About: Percheron Therapeutics Limited engages in the research and development of antisense pharmaceuticals for cancer and rare diseases in Australia. Its products pipeline includes HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed phase I clinical trial to treat to human v-domain immunoglobulin suppressor of T-cell activation (VISTA). The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Latest price: A$0.00 (-25.00%)
PER ASX Percheron Therapeutics Ltd
Percheron Therapeutics Ltd share price
PER price activity
Último preço
$ 0,000
Variação (24h)
-0,00 AUD (-25,00%)
Volume
3.32M
Volume (média 4 sem.)
-
Abertura
$ 0,00
Variação do dia
$ 0,00 - $ 0,00
Fechamento anterior
$ 0,00
Último negócio
05 Oct, 4:56 am GMT+0
Atrasado
05 Oct, 4:56 am GMT+0
PER price performance
Atrasado
05 Oct, 4:56 am GMT+0
quote.marketSignals